Johnson & Johnson on Thursday announced it has officially completed its $1 billion cash acquisition of Firefly Bio, Inc., bolstering the pharmaceutical giant’s oncology pipeline with a cutting-edge degrader antibody conjugate (DAC) platform.
The buyout introduces Firefly Bio’s proprietary Firelink™ DAC platform to Johnson & Johnson, enhancing its capabilities in targeted therapies and next-generation antibody engineering. The platform is specifically designed to deliver highly selective protein degraders directly to cancer cells while sparing healthy tissue, addressing critical limitations in treating hard-to-treat solid tumors, including KRAS-driven cancers.
“The completion of this acquisition marks an important step in advancing new approaches to better address difficult-to-treat solid tumors,” Dr. John Reed, executive vice president of Innovative Medicine, Research & Development at Johnson & Johnson said. “By bringing together Firefly Bio’s differentiated technology with our deep expertise in oncology and antibody engineering, we are well positioned to accelerate the development of more precise and effective therapies.”
Accounted for as an asset acquisition, the transaction will result in an in-process research and development charge of approximately $1 billion in the third quarter of 2026. Johnson & Johnson anticipates the deal will dilute its adjusted operational and reported earnings per share by roughly $0.46 in 2026 and $0.08 in 2027.
